Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology.
Proton magnetic resonance spectroscopy (MRS) is used to compare the chemistry of the transition, central and peripheral zones of the prostate. The assignments are made using two-dimensional correlated spectroscopy and the results compared with histopathology. The chemistry associated with benign prostatic hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and malignant biopsy tissues are described. There are distinct MR spectral patterns for glandular and stromal BPH, PIN and adenocarcinoma. Importantly, there are also different spectral patterns from BPH in the transitional and central zones when compared to BPH in the peripheral zone. A pattern recognition method is used to analyze the MR spectra from the biopsy specimens. The resultant mathematical classifiers generated a high level of accuracy (sensitivity and specificity of 100 and 97%). It was found that for this accuracy to be achieved, the classifiers need to be developed by comparing the spectra with specialist serial sectioned histopathology. With serial sectioned pathology the pattern recognition method was capable of identifying less than 5% of adenocarcinoma in a given piece of tissue. Many of the chemicals identified in the biopsy specimens are available for inspection from the prostate, in vivo, at 3 T.
Swindle
Peter
P
Department of Urology, Mater Hospital, Brisbane, QLD, 4210, Australia.
Ramadan
Saadallah
S
Stanwell
Peter
P
McCredie
Simon
S
Russell
Peter
P
Mountford
Carolyn
C
D000596:Amino Acids / Q000032:analysis; D001706:Biopsy; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D011467:Prostate / Q000033:anatomy & histology* / Q000473:pathology*; D011469:Prostatic Diseases / Q000175:diagnosis / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000473:pathology; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology*
D000596:Amino Acids
Prostate. 1995 May;26(5):275-80
7753713
Magn Reson Med. 1993 Feb;29(2):149-57
8429778
Int J Gynecol Cancer. 1995 May;5(3):211-221
11578479
Magn Reson Med. 2005 Feb;53(2):275-81
15678545
Prostate. 1981;2(1):35-49
7279811
Magn Reson Med. 2000 Jan;43(1):23-33
10642728
J Urol. 1999 Nov;162(5):1587-90
10524873
Biochem Biophys Res Commun. 1980 Jul 16;95(1):1-6
7417242
Int J Cancer. 1994 Oct 15;59(2):248-61
7927926
Lab Invest. 1998 Mar;78(3):319-33
9520945
Cancer. 1987 Feb 15;59(4):788-94
2433020
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15382-7
9860977
Eur J Biochem. 1992 Apr 15;205(2):827-39
1572374
Front Biosci. 1996 Jul 01;1:d103-17
9159218
Chem Rev. 2004 Aug;104(8):3677-704
15303833
J Biol Chem. 1986 Mar 5;261(7):3048-53
3949759
Magn Reson Med. 2005 Feb;53(2):249-55
15678552
Prostate. 1997 Mar 1;30(4):248-55
9111602
Magn Reson Med. 2003 Nov;50(5):944-54
14587005
Enzyme. 1981;26(6):281-7
7308179
Eur J Biochem. 1981 Feb;114(2):375-84
6163631
J Mol Biol. 1982 Aug 5;159(2):323-51
7143444
J Biol Chem. 1987 Nov 5;262(31):14875-8
3667610
Pathology. 1993 Jul;25(3):268-76
7903445
Radiology. 2005 Sep;236(3):903-10
16118169
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3523-6
6954498
Eur Urol. 1996;30(2):145-52
8875195
Cancer. 1996 Jul 15;78(2):330-6
8674012
JAMA. 1995 Feb 15;273(7):548-52
7530782
Prog Clin Biol Res. 1984;145:27-53
6201879
NMR Biomed. 1998 Oct;11(6):266-72
9802468
Am J Clin Pathol. 1968 Mar;49(3):347-57
5645095
Pathologica. 1994 Apr;86(2):128-41
7524011
Prostate. 1980;1(1):3-13
7024953
Radiology. 2003 Jul;228(1):144-51
12832578
Radiology. 1997 Sep;204(3):661-6
9280241
Cancer Res. 1997 Aug 15;57(16):3398-401
9270004
J Urol. 1995 Oct;154(4):1295-9
7544835
Prog Clin Biol Res. 1980;37:149-60
6155669
J Magn Reson Imaging. 2002 Oct;16(4):451-63
12353259
Neoplasia. 2000 Jan-Apr;2(1-2):166-89
10933075
Biochemistry. 1984 Dec 4;23(25):5895-7
6525339